相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat et al.
CLINICAL CANCER RESEARCH (2019)
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brain Tumors
J. Ricardo McFaline-Figueroa et al.
AMERICAN JOURNAL OF MEDICINE (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
J Wolf et al.
ANNALS OF ONCOLOGY (2018)
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
H. Kotani et al.
ONCOGENE (2016)
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
I. A. Netland et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender et al.
NATURE MEDICINE (2016)
A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC)
Tawesak Tanwandee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Results from the Phase II BASALT-1 Study
Johan F. Vansteenkiste et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies
M. I. Ilie et al.
ANNALS OF ONCOLOGY (2015)
Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Yuichi Ando et al.
CANCER SCIENCE (2014)
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Alba Matas-Cespedes et al.
CLINICAL CANCER RESEARCH (2014)
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas
Zhao-Shi Bao et al.
GENOME RESEARCH (2014)
Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances
Florian Cabillic et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A study of HER2 gene amplification and protein expression in gastric cancer
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma
Bomi Kim et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
Downregulation of uPAR and Cathepsin B Induces Apoptosis via Regulation of Bcl-2 and Bax and Inhibition of the PI3K/Akt Pathway in Gliomas
Ramarao Malla et al.
PLOS ONE (2010)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
R Abounader et al.
FASEB JOURNAL (2001)
分享论文
